Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
Katharina Borm, Martin R Jakobsen, Kieran Cashin, Jacqueline K Flynn, Paula Ellenberg, Lars Ostergaard, Benhur Lee, Melissa J Churchill, Michael Roche, Paul R Gorry
Retrovirology | BIOMED CENTRAL LTD | Published : 2016
Awarded by Australian National Health and Medical Research Council
We thank J. Sodroski for providing the pSVIII-Env plasmid controls used in this study, as well as pCMV Delta P1 Delta envpA and pHIV-1Luc plasmids. We also thank D. Mosier and R. Nedellec for supplying the NP2-CD4/CCR5 cells, and N. Shimizu and H. Hoshino for permission to use the NP2-CD4/CCR5 cells. Maraviroc was provided by Pfizer. This study was supported by a grant from the Australian National Health and Medical Research Council to PRG and MJC (APP1086178). KB is supported by a Victorian International Postgraduate Research Scholarship. JKF is supported by an RMIT Vice Chancellor's Postdoctoral Fellowship. KC and MR are supported by NHMRC Postdoctoral Training Fellowships. PRG was supported by an Australian Research Council (ARC) Future Fellowship. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.